| Former Sequenom Executive Charged With Faking It Derek Lowe submits: I wrote here about Sequenom (SQNM), a company which claimed to have developed an in vitro test for Downs Syndrome. The whole story dissolved into a heap of lawsuits, allegations of fraud, questions about whether Sequenom ever had such a test at all, and other craziness. Now the SEC has charged a former executive of the company with lying to investors. Elizabeth Dragon publicly touted the accuracy of the company's test several times, in front of large groups, before the roof came in. Here's the official complaint, and it's most interesting reading:Complete Story » seekingalpha.com |
PPD Celebrates 25 Years with Ringing of Nasdaq Opening Bell (Business Wire) WILMINGTON, N.C.----PPD, Inc. today announced it will ring the Nasdaq Stock Market Opening Bell on July 1 at 9:30 a.m. ET to commemorate PPD’s history as one of the world’s leading contract research organizations. us.rd.yahoo.com |
Biogen Pays Pretty Price to Expand ALS Pipeline EP Vantage submits:The list of unpartnered amyotrophic lateral sclerosis (ALS) treatments just got smaller. Biogen Idec (BIIB) has snapped up the phase III-ready neuroprotective drug KNS-760704 for $20m in cash and a $60m stake in privately-held Knopp Neurosciences, allowing the partners to advance the compound into pivotal trials in the first half of next year.As a result of the deal, KNS-760704 will join the now closely-watched olesoxime, which was cornered by Actelion (ALIOF.PK) earlier this month, in phase III trials for ALS. Mitsubishi Tanabe's edaravone and CytRx's arimoclomol are also in late stage studies. ALS patients currently have just one pharmaceutical treatment option, riluzole, which has modest benefits, so this deal increases the number of shots on goal for the fatal and debilitating disease. (Therapeutic focus – ALS field entering pivotal stage, August 2, 2010.)Complete Story » seekingalpha.com |
Is Celldex Therapeutics on the Rebound? VFC submits: Barely a week after news broke that Pfizer (PFE) had kicked Celldex Therapeutics (CLDX) to the curb sending the stock price into a steep and rapid decline, CLDX is already on the rebound with a more than twelve percent jump on Monday. There has been no news release that would justify the quick reversal, although a round of insider buying just days after the Pfizer news may have provided a boost in confidence for investors who were shaken and stirred by the bad news. That said, the purchases were for 3,000 shares (by Director Harry Penner) and 2,000 shares (by Officer Avery Catling), by no means convincing purchases. Complete Story » seekingalpha.com |
Senior Veterans Reflect - Video Veterans Share Life Lessons Learned in Service feedproxy.google.com |